Patents by Inventor Stefan Worgall

Stefan Worgall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease
    Patent number: 11510917
    Abstract: The disclosure provides a method comprising administering HIF stabilizing small molecule drugs to premature infants, whose survival is dependent upon mechanical ventilation and/or supplemental oxygen, to counteract the pathological effects of hyperoxia on lung development. Data in a mouse model of hyperoxia-induced neonatal lung disease supports a treatment with a HIF stabilizer during high oxygen exposure protects the lung. HIF stabilizers can be administered via various routes, including in an aerosolized state using a ventilator, intravenous, intraperitoneal or subcutaneous injection.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 29, 2022
    Assignee: CORNELL UNIVERSITY
    Inventors: Randi B. Silver, Stefan Worgall
  • HIF-STABILIZATION AND PREVENTION OF HYPEROXIA-INDUCED NEONATAL LUNG DISEASE
    Publication number: 20190298709
    Abstract: The disclosure provides a method comprising administering HIF stabilizing small molecule drugs to premature infants, whose survival is dependent upon mechanical ventilation and/or supplemental oxygen, to counteract the pathological effects of hyperoxia on lung development. Data in a mouse model of hyperoxia-induced neonatal lung disease supports a treatment with a HIF stabilizer during high oxygen exposure protects the lung. HIF stabilizers can be administered via various routes, including in an aerosolized state using a ventilator, intravenous, intraperitoneal or subcutaneous injection.
    Type: Application
    Filed: February 17, 2017
    Publication date: October 3, 2019
    Inventors: Randi B. SILVER, Stefan WORGALL
  • Methods to decrease susceptibility to asthmatic bronchoconstriction
    Patent number: 10159678
    Abstract: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: December 25, 2018
    Assignees: Cornell University, Columbia University
    Inventors: Stefan Worgall, Tilla S. Worgall
  • METHODS TO DECREASE SUSCEPTIBILITY TO ASTHMATIC BRONCHOCONSTRICTION
    Publication number: 20150139915
    Abstract: Methods and compositions are described for reducing airway reactivity and the susceptibility to asthmatic bronchoconstriction that involve increasing sphingolipid content in airways and lungs of a mammalian subject.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Stefan Worgall, Tilla S. Worgall
  • VACCINES FOR PREVENTION AND TREATMENT OF ADDICTION
    Publication number: 20110086063
    Abstract: The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody directed against the addictive drug. The invention further provides a method of inducing an immune response against an addictive drug or reducing the effect of an addictive drug in a human by ad-ministering to the human the aforementioned adenovirus-antigen conjugate or antibody encoding adenoviral vector.
    Type: Application
    Filed: June 4, 2009
    Publication date: April 14, 2011
    Applicant: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Philip L. Leopold, Stefan Worgall, Julie L. Boyer